PE20020376A1 - Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis - Google Patents
Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesisInfo
- Publication number
- PE20020376A1 PE20020376A1 PE2001000901A PE2001000901A PE20020376A1 PE 20020376 A1 PE20020376 A1 PE 20020376A1 PE 2001000901 A PE2001000901 A PE 2001000901A PE 2001000901 A PE2001000901 A PE 2001000901A PE 20020376 A1 PE20020376 A1 PE 20020376A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- plasminogen
- diagnosis
- peptide
- inhibit angiogenesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
SE REFIERE A UN PEPTIDO CONJUGADO QUE COMPRENDE UN PEPTIDO KRINGLE 1, 4-5 DE PLASMINOGENO; 5 DE PROTROMBINA FUNCIONALIZADO (SECUENCIAS DE AMINOACIDOS SIMILARES A PLASMINOGENO) ACOPLADO QUIMICAMENTE A UN POLIMERO FUNCIONALIZADO (POLIALQUILENGLICOL COMO POLIETILENGLICOL, METOXIPOLIETILENGLICOL DE PESO MOLECULAR 5000 A 40000) A TRAVES DE UNA UNION PUENTE OXIMA O CARBONO-NITROGENO. EL CONJUGADO AL CONTENER FRAGMENTOS DE PEPTIDO KRINGLE AUMENTA LA VIDA MEDIA Y EL TIEMPO DE CIRCULACION E INHIBE LA PROLIFERACION DE CELULAS ENDOTELICAS PUDIEDO SER UTIL PARA EL TRATAMIENTO DE ANGIOGENESIS EN CANCER, ARTRITIS, DEGENERACION MACULAR, RETINOPATIA DIABETICA, CARCINOMAS, SARCOMAS, LINFOMAS, PSORIASIS, HEMAGIOMAS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67522600A | 2000-09-29 | 2000-09-29 | |
US94270401A | 2001-08-31 | 2001-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020376A1 true PE20020376A1 (es) | 2002-05-13 |
Family
ID=27101293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000901A PE20020376A1 (es) | 2000-09-29 | 2001-09-07 | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1320589B1 (es) |
JP (2) | JP2004526416A (es) |
AR (1) | AR030631A1 (es) |
AT (1) | ATE410507T1 (es) |
AU (1) | AU2002211837A1 (es) |
BR (1) | BR0110421A (es) |
CA (1) | CA2420672A1 (es) |
DE (1) | DE60136084D1 (es) |
ES (1) | ES2313987T3 (es) |
MX (1) | MXPA03002778A (es) |
PE (1) | PE20020376A1 (es) |
UY (1) | UY26929A1 (es) |
WO (1) | WO2002026782A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2502304C (en) | 2002-10-08 | 2013-10-01 | Genencor International, Inc. | Phenolic binding peptides |
AU2012203658B2 (en) * | 2007-01-10 | 2014-05-08 | Protgen Ltd. | Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof |
CN101219219B (zh) * | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
FR2915102B1 (fr) * | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
KR20120083905A (ko) | 2009-10-09 | 2012-07-26 | 자프겐 코포레이션 | 비만의 치료에 사용하기 위한 설폰 화합물 |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
US20130023513A1 (en) | 2010-01-12 | 2013-01-24 | Hughes Thomas E | Methods and Compositions for Treating Cardiovascular Disorders |
WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
CN103249735B (zh) | 2010-07-22 | 2016-04-06 | 扎夫根股份有限公司 | 三环化合物及其制备和使用方法 |
WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
US9189078B2 (en) | 2010-12-20 | 2015-11-17 | Apple Inc. | Enhancing keycap legend visibility with optical components |
BR112013018771A2 (pt) | 2011-01-26 | 2019-09-17 | Zafgen Inc | compostos de tetrazol e métodos para fazer e usar os mesmos |
CA2835195A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
WO2012154679A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
US9290472B2 (en) | 2011-05-06 | 2016-03-22 | Zafgen, Inc. | Partially saturated tricyclic compounds and methods of making and using same |
EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
KR20140112565A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
US9440943B2 (en) | 2012-01-18 | 2016-09-13 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
AU2013259617A1 (en) | 2012-05-08 | 2014-11-27 | Zafgen, Inc. | Treating hypothalamic obesity with MetAP2 inhibitors |
WO2013169860A1 (en) | 2012-05-09 | 2013-11-14 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
SG11201503521QA (en) | 2012-11-05 | 2015-06-29 | Zafgen Inc | Methods of treating liver diseases |
AU2013337288A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
CA2890342A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
CA2904353A1 (en) | 2013-03-14 | 2014-09-25 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2204726A1 (en) * | 1994-11-09 | 1996-12-27 | Robin E. Offord | Functionalized polymers for site-specific attachment |
NZ307044A (en) * | 1995-04-26 | 2002-03-01 | Childrens Medical Center | Angiostatin fragments with antiangiogenic activity |
EP0910571B1 (en) * | 1996-05-03 | 2005-07-20 | Abbott Laboratories | Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
ATE279430T1 (de) * | 1998-03-05 | 2004-10-15 | Chiron Corp | Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen |
DE69925830T2 (de) * | 1998-04-28 | 2006-05-04 | Applied Research Systems Ars Holding N.V. | Peg-lhrh analog konjugate |
KR20000018933A (ko) * | 1998-09-07 | 2000-04-06 | 김승수 | 내피세포 성장억제 활성을 가지는 사람 프로트롬빈 크링글단백질 및 이를 암호하는 유전자 |
-
2001
- 2001-09-07 AR ARP010104263A patent/AR030631A1/es unknown
- 2001-09-07 UY UY26929A patent/UY26929A1/es not_active Application Discontinuation
- 2001-09-07 PE PE2001000901A patent/PE20020376A1/es not_active Application Discontinuation
- 2001-09-27 DE DE60136084T patent/DE60136084D1/de not_active Expired - Fee Related
- 2001-09-27 WO PCT/US2001/042423 patent/WO2002026782A2/en active Application Filing
- 2001-09-27 AT AT01979922T patent/ATE410507T1/de not_active IP Right Cessation
- 2001-09-27 EP EP01979922A patent/EP1320589B1/en not_active Expired - Lifetime
- 2001-09-27 ES ES01979922T patent/ES2313987T3/es not_active Expired - Lifetime
- 2001-09-27 BR BR0110421-7A patent/BR0110421A/pt not_active Application Discontinuation
- 2001-09-27 AU AU2002211837A patent/AU2002211837A1/en not_active Abandoned
- 2001-09-27 MX MXPA03002778A patent/MXPA03002778A/es active IP Right Grant
- 2001-09-27 JP JP2002531165A patent/JP2004526416A/ja not_active Withdrawn
- 2001-09-27 CA CA002420672A patent/CA2420672A1/en not_active Abandoned
-
2008
- 2008-04-02 JP JP2008095692A patent/JP2008231107A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1320589B1 (en) | 2008-10-08 |
CA2420672A1 (en) | 2002-04-04 |
WO2002026782A2 (en) | 2002-04-04 |
ATE410507T1 (de) | 2008-10-15 |
WO2002026782A3 (en) | 2003-01-16 |
EP1320589A2 (en) | 2003-06-25 |
AR030631A1 (es) | 2003-08-27 |
ES2313987T3 (es) | 2009-03-16 |
MXPA03002778A (es) | 2004-05-04 |
BR0110421A (pt) | 2005-08-30 |
JP2008231107A (ja) | 2008-10-02 |
AU2002211837A1 (en) | 2002-04-08 |
DE60136084D1 (de) | 2008-11-20 |
JP2004526416A (ja) | 2004-09-02 |
UY26929A1 (es) | 2002-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020376A1 (es) | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis | |
GEP20084486B (en) | Polymer conjugates of interferon-beta with enhanced biological potency | |
ES2181006T3 (es) | Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion. | |
WO2000026368A3 (en) | Therapeutic antiangiogenic endostatin compositions | |
PE20020355A1 (es) | Genes involucrados en la produccion de un compuesto isoprenoide | |
ATE255608T1 (de) | Polymer | |
AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
PE20060880A1 (es) | Conjugados de polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas | |
DK0973819T3 (da) | Ikke-antigene forgrenede polymerkonjugater | |
ATE229043T1 (de) | Polymer | |
BR0317822A (pt) | Composição fluoroquìmica | |
DE602004029699D1 (de) | Nukleinsäuren zum auslösen der tumorzellsterblichkeit | |
WO2000069470A3 (en) | Improved cellular uptake of bioactive agents | |
AR008907A1 (es) | Conjugados utiles en el tratamiento del cancer de prostata | |
AR032574A1 (es) | Conjugados peg de hgf-nk4 | |
RS50857B (sr) | Konjugati polimera neublastina i postupci za njihovu upotrebu | |
ES2157862A1 (es) | "nuevas actividades farmacologicas de los extractos del curcuma longa" | |
DE602004028266D1 (de) | Angiogene peptide und ihre verwendungen | |
BR9810242A (pt) | Composições úteis como selante de fibrina | |
DE10084241D2 (de) | Heparin mit mittlerer Molmasse | |
ATE303430T1 (de) | Polymerisate als steuerbare dispergiermittel | |
ZA9915B (en) | Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer. | |
ATE388479T1 (de) | Löschkammer und hochleistungsschalter mit starker lichtbogenbeblasung | |
ATE349472T1 (de) | Alkoxylierte diallylaminderivate enthaltende wasserlösliche oder in wasser dispergierbare polymerisate | |
BR0010738A (pt) | Enzima subtilase do sub gupo i-s1 ou i-s20, enazima subtilase isolada, variante de subtilase, sequência de dna isolada, vetor de expressão, célula hospedeira microbiana, hospedeiro microbiano, método para a produção de uma subtilase ou uma variante de subtilase, composição, e, uso de uma subtilase ou uma variante de subtilase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |